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Steve A Ward1*† and Ian C Boulton2†Abstract
The CRIMALDDI Consortium has been a three-year project funded by the EU Framework Seven Programme. It
aimed to develop a prioritized set of recommendations to speed up anti-malarial drug discovery research and con-
tribute to the setting of the global research agenda. It has attempted to align thinking on the high priority issues
and then to develop action plans and strategies to address these issues. Through a series of facilitated and inter-
active workshops, it has concluded that these priorities can be grouped under five key themes: attacking artemisinin
resistance; creating and sharing community resources; delivering enabling technologies; exploiting high throughput
screening hits quickly; and, identifying novel targets. Recommendations have been prioritized into one of four
levels: quick wins; removing key roadblocks to future progress; speeding-up drug discovery; and, nice to have (but
not essential). Use of this prioritization allows efforts and resources to be focused on the lines of work that will con-
tribute most to expediting anti-malarial drug discovery. Estimates of the time and finances required to implement
the recommendations have also been made, along with indications of when recommendations within each theme
will make an impact. All of this has been collected into an indicative roadmap that, it is hoped, will guide decisions
about the direction and focus of European anti-malarial drug discovery research and contribute to the setting of
the global research agenda.
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Malaria remains a major cause of mortality and morbid-
ity throughout the developing world, especially in sub-
Saharan Africa, but also in India, Latin America, and
Southeast Asia. In 2010, there were still 216 million
cases and 655,000 deaths attributed to the disease [1]. It
is now well established as a key challenge for the global
community and a focus for international development,
health funding, and assistance. Starting with the launch
of the Roll Back Malaria Partnership in 1998 [2], there
has been increasing recognition of the unacceptable so-
cial and economic impacts malaria makes on affected
countries, as well as the suffering it brings to patients
and their families. The Abuja Declaration of 2000 [3]
underlined the commitment of African governments to
work towards significantly reducing the burden in sub-
Saharan Africa and the need for the world to reprioritize* Correspondence: saward@liverpool.ac.uk
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distribution, and reproduction in any mediumit after a relative lack of interest following the ending of
the Global Malaria Eradication Programme (GMEP) in
1969. Significant resources are now channelled towards
malaria control through agencies such as the Global
Fund to fight AIDS, Tuberculosis and Malaria, the US
President’s Malaria Initiative, the World Bank Global
Strategy and Booster Program, and many others. However
the development of new technologies and the past suc-
cesses of GMEP in eliminating malaria from Europe, North
America, the Caribbean, and parts of Asia and South-
Central America have now opened up the possibility of
once again seeking to eliminate and ultimately eradicate
malaria globally [4]. The Malaria Forum in October 2007
(convened by the Bill and Melinda Gates Foundation) is-
sued the challenge to the world to move from a control
and containment strategy to embrace the ultimate goal of
eventually eradicating the disease [5]. This was rapidly em-
braced by the World Health Organization (WHO), the Roll
Back Malaria Partnership (RBM), and many other organi-
zations and institutions. The development of the Globalentral Ltd. This is an open access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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the initial stages of this long-term process [6].
The GMAP emphasized the need for a proper research
and development agenda to develop the new tools which
would be required to meet all the challenges. This led to
the establishment of the MalERA Initiative – a two-year
programme to develop a research agenda across all the
disciplines and approaches relevant to tackling the dis-
ease. A recent series of papers has detailed the findings
of this major collaborative project [7]. The importance
of drug treatment to meeting the elimination (and
ultimately eradication) challenge has been recognized
from the outset.
CRIMALDDI consortium
The CRIMALDDI Consortium was established in 2008
under a European Union Seventh Framework Programme
Coordination grant. It has been a three-year project to
develop a coordinated action plan for future research
programmes and funding opportunities to inform the
European anti-malarial drug research agenda for the next
decade and also contribute to the discussions on setting
the global agenda. As such it complements initiatives such
as MalERA by developing more detailed plans for the high
priority challenges that need to be addressed in the next
five to ten years if the community is to be able to develop
the drugs it needs for malaria elimination and eradication.
It also focuses on the priorities that need to be addressed
in the next five years as opposed to the MalERA Drug Re-
search Agenda’s focus on drugs that will be needed specif-
ically for eradication [8]. An earlier paper has outlined the
work of the Consortium and its methodology [9].
The Consortium members identified five priority work
streams to focus attention on. The approach of each work
stream was to bring together global experts in a series of
one- or two-day facilitated and interactive workshops to
address the work stream topic. The participants in these
workshops were global experts both within the field of
malaria and from related fields. The introduction of ex-
perts from outside malaria was to try and bring new think-
ing to the topics under discussion. The five topics were:-
 Artemisinin resistance;
 Managing the wealth of new high throughput
screening (HTS) data;
 Plasmodium falciparum and Plasmodium vivax
novel targets and classes;
 Stage-specific screening methods;
 Using chemistry to understand biology.
The workshops were run between March and October
2010 and reports of the discussions can be found on the
CRIMALDDI website [10] and in the Additional file 1,
Additional file 2, Additional file 3, Additional file 4 andAdditional file 5. The recommendations of the workshops
and of the Consortium were periodically reviewed by an
Expert Advisory Group (EAG). Reports of the EAG meet-
ings can also be found on the CRIMALDDI website and
in the Additional file 6, Additional file 7, Additional file 8
and Additional file 9. The EAG reviewed the recommen-
dations according to three agreed parameters:
 Progress of the Consortium against the objectives
established at the outset of the Project and agreed
with the European Commission;
 Coordination of the outputs and recommendations
with other malaria research and development
initiatives;
 Alignment to ensure that adequate attention has
been given by the workshops to the drug discovery
process.
Five key themes
Inevitably there was some overlap in the recommenda-
tions of the five workshops, but it became clear that the
findings could be grouped under five key themes:
 Attacking artemisinin resistance;
 Creating and sharing community resources;
 Delivering enabling technologies;
 Exploiting HTS hits quickly;
 Identifying novel targets.
Each of these priority themes is important in moving
drug discovery forward quickly to ensure that there is a
portfolio of new products available to fill the demands of
malaria control and elimination as well as guarding against
the loss of any of the currently available anti-malarial drug
products. These are summarized in Table 1.
Attacking artemisinin resistance
Artemisinin derivatives and artemisinin-containing com-
bination therapy are now central to the first-line treat-
ment of P. falciparum malaria. The recent emergence of
decreased sensitivity of the parasite to artemisinins in
Cambodia is of grave concern and puts at risk the entire
strategy for the treatment of malaria [11]. Considerable
effort is being put into the discovery of anti-malarials,
which have similar modes of action to the current arte-
misinin derivatives or contain pharmacophores similar
to the endoperoxide bridge. Examples of this type of
work are the synthetic endoperoxide OZ439, sponsored
by Medicines for Malaria Venture (MMV) [12], and in-
vestigations underway at the University of Liverpool
into tetraoxanes as anti-malarials [13]. It is crucial to
the future of this work that an understanding of the
mechanism of artemisinin resistance and the degree of
cross-resistance to other chemotypes, including the
Table 1 Five key themes
Key theme Rationale behind the theme
Attacking artemisinin resistance Artemisinin-based combination therapy is fundamental to the control of malaria. The appearance of tolerance
to artemisinins seen in Southeast Asia could threaten current control and elimination efforts. Understanding
the mechanism of resistance is fundamental to designing future anti-malarials.
Creating and sharing community
resources
Improved sharing of information about all aspects of anti-malarial drug discovery will help to speed up drug
development. Strategies have been identified to improve information sharing in order to focus effort and re-
duce duplication.
Delivering enabling technologies Anti-malarial drug discovery is being held up, especially for P. vivax, because certain enabling technologies
are not in place. The development of these will be the key to discovering novel drugs.
Exploiting HTS hits quickly The structures of about 20,000 compounds that have given positive hits in HTS are now publicly available.
Recommendations are made to filter this unparalleled amount of information quickly and efficiently to
identify the most promising leads and move them quickly into drug development.
Identifying novel targets At present drug development is focused on a few well-characterized drug targets, nearly all in the blood
stage of P. falciparum infections. The search for new drug targets is constrained by the poor understanding of
the underlying biology of the parasite’s life cycle in humans. New targets need to be identified and validated.
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to this question will either close off the endoperoxides
as potential future drugs or redirect work on novel
structures retaining this functional group. For these rea-
sons, developing an understanding of the mechanism of
resistance and its implications for drug discovery was
prioritized.
Exploiting high throughput screening hits quickly
The publication of the structures of 13,500 compounds
with high levels of activity in high-throughput primary
screens against P. falciparum by GlaxoSmithKline (GSK)
[14] and the St Jude’s Group [15] has given the malaria
community a very large resource to tap into. These
structures (together with more recent additions from
other library screens) are publicly available through the
ChEMBL [16] and Collaborative Drug Discovery [17] da-
tabases. In total there are about 20–25,000 anti-malarial
“hit” structures available in publicly accessible databases.
Drug discovery groups can use these to find new drug
types and take them forward towards full drug develop-
ment. However, only a few tens of these positive hits can
realistically be progressed to full drug development.
Through logical and properly validated processes, the
structures must be filtered down to a manageable num-
ber. The community needs to have mechanisms for en-
suring that the duplication of work is minimized and
that this unique resource’s value is maximized. This in
turn requires the global anti-malarial drug discovery
community, as far as possible, to be aware of who is
working on what within the community to ensure the
timely sharing of information.
One of the problems identified from the publication of
the active structures by GSK, Novartis and St Jude’s was
how the community would be able to access quantities
of the chemical compounds in order to carry out further
work. The need for medicinal chemistry resources tomake these compounds more readily available in a struc-
tured and monitored way was highlighted. MMV has
subsequently responded to this challenge in part through
the collation of the “Malaria Box” of some 400 chemical
hits that are representative of the drug-like and probe-
like molecules form the full collection. This physical set
of compounds is available for researchers free of charge
through MMV [18] and should serve as a catalyst to on-
going discovery research.
Identifying novel targets
Since the publication of the malaria genome, there have
been numerous efforts aimed at identifying and validat-
ing novel drug targets. Despite these efforts, the reality
is that much anti-malarial drug discovery is still focused
on a limited number of historic targets (the folate and
haemoglobin degradation pathways are prime examples),
and primarily on the blood stage of the parasite’s life
cycle. There is presumably a wealth of untapped targets
in the proteome (or rather proteomes) of the various de-
velopmental stages of the parasite that can be targeted.
It is understandable that drug discoverers will be drawn
to working on well characterized targets but the real ad-
vances in treatment in the past have been delivered
when new targets or compound classes have been identi-
fied (as with artemisinins). In particular, the increasing
awareness of the burden from P. vivax infections and
the real paucity of drugs to treat them (especially the
liver stage infections) underline the need to look more
widely for novel targets [19,20]. A variety of approaches
should be adopted to increase the chances of finding
new targets, and many research groups will need to en-
gage in order to bring momentum to this intellectually
demanding challenge. However, if all this effort remains
focused on a few existing targets and there is unproduct-
ive duplication of effort, then progress in overcoming
the gaps in the current drug portfolio will be too slow.
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As mentioned under “exploiting HTS hits quickly”, the
malaria community may be moving forward more slowly
in finding new drugs than it could. An absence of ways
to collaborate and share information is contributing to
this. The sharing of information about who is working
on what and how successful they are (while not either
compromising commercial confidentiality or academic
demands for high-impact publications) would allow for
better management of the limited resources and ensure
that quantities of compounds that can be made available
are not wasted.
The structural information now publicly available has
come from the screening of specific chemical libraries.
However there are a number of other types of libraries
that have not yet been tapped into – especially those
from the agrochemical sector. Tools to further filter the
structures against knowledge of what is druggable and
what is not have yet to be fully applied to these results.
Not yet fully developed are the structures and processes
within the malaria community to ensure that there is
minimal unnecessary duplication of effort. Any research
group can work in the same area as another if they think
they will bring a new insight to that area, in fact compe-
tition can often drive the speed of delivery. That said,
the priority should be, in times of restricted resources,
to try to minimize unnecessary duplication.
Delivering enabling technologies
Finding new anti-malarials is constrained by the lack of
key enabling technologies. The current inability to culture
infected hepatocytes long term and to screen for activity
against hypnozoites is a major roadblock to identifying
new drugs to treat recurrent P. vivax infections. Similarly
the inability to culture and screen compounds for activity
against other stages in the Plasmodium life cycle, especially
in other species that infect humans, severely restricts the
ability to look at these stages for possible new ways to at-
tack the parasite. As the drug discovery agenda shifts away
from just treating acute P. falciparum infections to eradi-
cating asymptomatic reservoirs of parasites, progress will
be slow if the tools to probe activity outside of the infected
blood stages are not available. Focusing on the key enabling
technologies that will break through the developmental
roadblocks will, if successful, speed up finding new drugs
to fill in the gaps needed not only to continue with the
control phase of GMAP, but also the elimination phase.
Prioritized recommendations
A lengthy “wish list” of lines of research and technolo-
gies whose development can be justified will not neces-
sarily be of great value to the institutions funding such
work. The resources that the major funding agencies are
able to devote to malaria research may have peaked [21].This is due both to the ongoing economic climate and
also to calls on their resources to support research and
development in other diseases. It can be difficult for
these organizations to decide on where the priorities
should be placed, especially if they are merely respond-
ing to research proposals and not pro-actively defining
their own agenda. One of the objectives of the CRIM-
ALDDI Project was to develop a prioritized and coordi-
nated set of recommendations that could contribute to
the debate over priority setting. By bringing together a
range of expertise from across the disciplines involved in
anti-malarial drug discovery and the related enabling
technologies, it was possible to suggest a more focused
set of recommendations that will expedite the work
needed to meet the objectives of the GMAP [6]. In par-
ticular, the recommendations for drug discovery research
could be focused on those programmes that will exped-
ite the development of the drug tools needed when the
current tools either lose their usefulness or do not meet
the changing requirements of the elimination and eradi-
cation stages of GMAP.
The CRIMALDDI Consortium process took the rec-
ommendations developed during the interactive work-
shops and attempted to prioritize them according to
their contribution to accelerating drug discovery. It then
attempted to make a first estimate of the time and cost
that will be needed to achieve the goal of each recom-
mendation. It also indicated when the recommendations
under each key theme could be expected to have an im-
pact. This roadmap both met the objective of developing
a coordinated plan to inform decisions on European
Union support for anti-malarial research and also to con-
tribute to the debate on a global agenda in response to the
call from the MalERA Consultative Group on Drugs [8].
Methods
Prioritization
The series of interactive workshops held in 2010 pro-
duced a range of recommendations that have been
described earlier. The CRIMALDDI Management Team
then met at the start of 2011 to agree on how these
could be clustered into the five key themes that had
been identified as running through the workshop find-
ings. Inevitably there was a degree of overlap and repli-
cation between the findings and this was eliminated.
Some recommendations were merged together where it
was judged that they covered much the same ground or
were elements of a larger need.
Once the list of recommendations had been agreed, the
team then agreed on a scheme to prioritize items. Four
levels of priority were felt to be appropriate (Table 2):
Important quick wins: recommendations that fell
under this heading would be those that could be
Ta
Im
Re
to
Sp
di
Table 2 Prioritization of recommendations
Important quick wins Activities that require only a few
resources and can be achieved in a
short period of time (less than one year)
Removing key roadblocks
to future progress
Major obstacles to future programmes
that must be overcome before key drug
discovery programmes can progress
expeditiously
Speeding-up drug
discovery
Recommendations that will speed up
progress but were not considered as
roadblocks to new drug discovery for
malaria control and elimination
Nice to have Useful recommendations that would
not significantly hold up drug discovery
if they were not pursued
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than 12 months) and for relatively little cost. They
might include holding consensus meetings, or
improving access to existing resources. The
implementation of such recommendations would allow
other lines of work to proceed, but to complete them
would require only a small amount of resource.
Removing key roadblocks to future progress:
recommendations that fell under this heading would be
those that seriously impede progress in key aspects of
anti-malarial drug discovery. Without removing these
roadblocks, there would be little prospect of delivering
the major tools necessary to meet the pre-elimination
and elimination goals developed under GMAP. Such
roadblocks would require a major effort to remove
them, and work on them should start as soon as
possible.
Speeding-up drug discovery: recommendations that
fall under this heading would, if implemented, ensure
that anti-malarial drug discovery could be speeded up
significantly. However, if they were not implemented,
there are existing approaches or levels of knowledge
that would allow research to continue, albeit more
slowly and with more difficulty. Investing in recom-
mendations prioritized under this heading should beble 3 Priorities – attacking artemisinin resistance
portant quick wins • Establish a clear definition of artemisinin “res
failure and parasite clearance times. Include a
parasite killing across the 48-hr erythrocytic c
• Greatly improve access to resistant parasites
moving key roadblocks
future progress
• Define the molecular and cellular basis of art
dormancy and/or reduced susceptibility
• Identify discriminatory phenotypes by system
eeding-up drug
scovery
• Establish stable resistant parasite lines to imp
mechanisms
• Identify and evaluate an appropriate range o
artemisinin resistanceconsidered once adequate resources have been put be-
hind removing the key roadblocks.
Nice to have: the final heading under which
recommendations could be grouped was those that could
be judged to be of interest and would contribute to anti-
malarial drug discovery or to developing key enabling
technologies. However recommendations that fell under
this heading were considered not to significantly hold up
drug discovery if they were not implemented. Investment
in these should only be considered if the recommenda-
tions under the other headings had been fully resourced.
Prioritization under each heading was achieved through
weighting the potential gains of each recommendation.
Estimating costs and timing
Once the prioritization had been completed, the next step
to meet the objectives of the Project was to make a first
estimate of costs and timings for each recommendation. A
meeting was held between members of the Management
Team and Medicines for Malaria Venture to develop this.
Inevitably this exercise would only be able to develop with
order-of-magnitude estimates. A particular research pro-
ject may be lucky and the solution found in a shorter
period of time and for less cost than estimated. Alterna-
tively it may be unlucky and require considerably longer
than the estimates arrived at. There are many factors that
would need to be considered in further refining this into a
fully costed action plan, or to develop elements into a pro-
ject proposal for a funding agency. For an initial exercise
like this, it has been necessary to make reasonable as-
sumptions and estimates to complete the exercise. How-
ever the estimates are of value in showing to the malaria
community and its funders both the relative scale of re-
sources needed to achieve this plan, and the timescale
over which it may need to maintain support to ensure a
reasonable chance of success.
Prioritized recommendations
Attacking artemisinin resistance
Table 3 shows the prioritization for this key theme. The
prioritization was driven by the urgent need to generateistance”, stemming from a clinical observation of increased treatment
broad profile of how resistance manifests itself, such as the window of
ycle and correlation of PCT with the experimental in vitro parameters
in order to broaden as far as possible groups able to work on resistance
emisinin-induced dormancy and develop easier to measure markers of
atic re‐evaluation all of the in vitro assays available
rove access and broaden number of groups able to study resistance
f “omic” approaches to search for discriminatory tools and markers of
Table 6 Priorities – exploiting high throughput screening
hits quickly
Removing key roadblocks
to future progress
• Establish a single repository for
compounds identified as positive
screening hits and increase availability of
these compound “powders” including
increased medicinal chemistry resources
to synthesize the compounds
Speeding-up drug
discovery
• Continue routine screening of
compound libraries and prioritization of
positive hits in secondary screening.
Agrochemical libraries are a particular
priority
Table 5 Priorities – delivering enabling technologies
Removing key roadblocks
to future progress
• Develop in vitro and in vivo culture
methods, models, and assays that can be
used widely and inexpensively to study
P. vivax infections across all stages of the
parasite life cycle and to screen drugs
more effectively for activity
• Elucidate the causes/biology of
hypnozoite dormancy in P. vivax
infections and so develop markers to
differentiate hypnozoites from active
infected hepatocytes
Speeding-up drug
discovery
• Precisely define and develop novel
methods and assays for evaluating drug
activity against each stage of the
parasite’s life cycle (with priority on early
ring stages)
• Develop an affordable humanized
mouse model
• Develop a standardized, robust and
transferable culture system for the study
of P. falciparum and P. vivax liver stages
• Develop a robust and reliable falciparum
and vivax exo-erythrocytic stage culture
and assay system
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“artemisinin resistance”. Once the necessary definitions
of resistance had been agreed, as many groups as pos-
sible should be in a position to use a wide range of tech-
niques to elucidate the mechanisms of resistance and so
enable drug discoverers to direct their efforts appropri-
ately. Given the importance of artemisinin-containing
combination treatments (ACT) for the control of P. fal-
ciparum malaria, a process of “letting a hundred flowers
bloom, one hundred schools of thought contend” [22]
was agreed to be the most likely to answer this vital and
pressing question in the shortest time.
Creating and sharing community resources
Table 4 shows the prioritization for this key theme. The
priority in this area is for more transparency and sharing
of information, particularly data about the properties of
potential new drug candidates. Given that resources in
the field are not limitless, and that the community needs
to ensure that unnecessary duplication of work is avoided,
easy access to this information will allow better decision-
making by funders and research teams on which lines of
investigation to pursue.
Delivering enabling technologies
It was clear from the discussions of the Consortium dur-
ing the initial phases of this project that several key enab-
ling technologies had to be developed rapidly to enable
vital drug discovery research activities to progress. This
was most noticeable in developing an understanding of
the underlying biology of the liver stages of malaria (par-
ticularly P. vivax). The results of the prioritization for this
key theme are shown in Table 5.
Exploiting high throughput screening hits quickly
The malaria community now has access to an unprece-
dented amount of structural information to inform drug
discovery and candidate identification. However the
prioritization was driven by the need to fully exploit this• Emphasize development of better
understanding of absorption, distribution,
metabolism, and elimination (ADME) and
toxicology of positive hits early in the
discovery process
• Use information on parasite resistance to
chemical classes to probe underlying
biological processes
• Evaluate the speed of action and stage
specificity of current HTS hits (currently
15.000‐20,000 novel chemotypes) to
identify new chemotypes with similar
pharmacodynamics to artemisinins. This
should include evaluation against
parasites with stable resistance to
artemisinins (and other anti-malarials)
and parasites arising from resistance
“hot spots”
Table 4 Priorities – creating and sharing community
resources
Removing key roadblocks
to future progress
• Develop and roll out a single reference
database of information on compounds
that are being investigated in malaria,
integrate it with the various current
databases on genes and metabolic
pathways and ensure all are properly
maintained
• Improve communication between active
research groups in malaria including
sharing materials and resources and
adoption of standard procedures for the
in vivo and in vitro investigation of
especially urgent challenges such as
artemisinin resistance
Table 7 Priorities – identifying novel targets
Important quick wins • Better definition of what constitutes target validation to ensure that novel targets are real and practical
Speeding-up drug discovery • Focus on looking for novelty in the first 12 hours of the ring stage (to ensure rapid kill of parasites as seen with
artemisinins) and in the last 12 hours of the schizont stage
• Focus on identifying targets other than haem in the blood stages of malarial infections
• Using currently available mathematical tools and models developed in other biological fields to develop
mathematical models of biological pathways in the malaria parasite to improve understanding of the underlying
biology and identify possible novel targets
• Phenotype parasite strains that are affected differently by each chemical class to identify characteristics that may
be used to identify novel targets
• Focus on increased understanding of the activity of current anti-malarials in high priority areas (e g, activity of
8-aminoquinolines in hypnozoites, effect of antibiotic pre-treatment on apicoplasts)
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ered necessary to have in place systems and resources to
ensure that this information is filtered rapidly down to a
manageable number of compounds that can be taken
through to full development in a reasonable period of
time. Table 6 shows the prioritization for this key theme.
Identifying novel targets
Much of the focus of anti-malarial drug discovery is still
on the well-characterized targets in the blood stages of
the Plasmodium life cycle. There are likely to be many
tractable targets elsewhere in the life cycle and these will
become more apparent once there is targeted research
into these life cycle stages. Many of the challenges that
will be encountered in the pre-elimination and elimin-
ation stages of GMAP are probably only solvable if new
targets are identified and drugs targeted at them are de-
veloped. Therefore, there needs to be more focus on in-
vestigating these under-exploited aspects of the
Plasmodium life cycle. The results of the prioritization
for this key theme are shown in Table 7.Table 8 Priorities – nice to have
Delivering enabling technologies • Establish reporter systems for every st
• Improve imaging tools for mechanism
• Develop tools and reagents that have
(antibodies, affinity tags)
• Investigate the possibility of using a m
activity against hypnozoites in primar
• Develop a P. falciparum and P. vivax o
• Develop of a gametocyte motility ass
• Develop tools to image the parasite’s
algorithms) that have proved useful in
properly in malaria
• Investigate how far one could use To
Exploiting HTS hits quickly • Phenotype parasite strains affected di
in compound activity
Identifying novel targets • Use available IT tools to cluster structRoadmap
The recommendations that were prioritized as “Nice to
have” were not considered further for costing and tim-
ing. It was considered unlikely that the resources that
would be available for anti-malarial drug research would
stretch to include these activities at this time. However
they still had some value and alternative funding streams
might be available to allow them to proceed. They are
shown in Table 8.
“Quick wins” and “Removing key roadblocks” were
judged to be of sufficient importance that they should
proceed as soon as possible. It was estimated that
around one year would be needed for all the resourcing
to be put in place. Recommendations prioritized under
“Speeding-up drug discovery” are likely to be possible as
resources become available, once the other priorities
have been properly funded. Therefore, since it is not
possible at this stage to estimate when funding agencies
will have the necessary resources to support these, the
timing has only been shown in terms of duration and to
show any timing dependencies.age of the parasite life cycle
s of parasite drug resistance
proved useful in other fields but are not yet available for malaria
ature gametocyte and/or liver schizont assay system as a surrogate for
y screening for novel anti-vivax drugs
okinete assay to complement the current Plasmodium berghei assay
ay
response (metabolomics, proteomics, transcriptomics, structural
other diseases (e g, tuberculosis) but have not yet been developed
xoplasma as a model for Plasmodium
fferently by each chemical class to identify possible causes of differences
ures around identified biological activity against Plasmodium
Figure 1 Time to impact of key themes. Each key theme will
make an impact at a different time from when initial investment is
made in it. The five key themes have been grouped according to
when impact can be expected, and so can direct funders towards
the themes that best match their time horizons for impact.
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proaches to when they want to see an impact from their
investment. The five key themes can be grouped accord-
ing to when they are likely to have an impact on anti-
malarial drug discovery. Basically, those themes that can
have a discernible impact within five years of the initial
investment (short term) are those that better exploit
current tools. Those that can deliver an impact in ten
years (medium term) are laying the foundations for fu-
ture drug discovery. Finally, those that are not expected
to have an impact within ten years (long term) are dis-
covering the new tools that will be needed to meet the
objectives of GMAP and malaria control, elimination
and eradication. Figure 1 shows how the key themes
have been grouped in this way.
Figures 2, 3 and 4 show the roadmap as developed by
the process outlined earlier. They were developed by
making reasonable assumptions on probabilities of suc-
cess (as agreed within the CRIMALDDI Consortium).
Conclusion
If the ambitious goal of eradicating malaria is to be
achieved in the foreseeable future, then a series of new
drug tools will be required to meet the new challenges.Figure 2 Action plan to deliver “quick wins”. The estimates of costs and
as “quick wins”.Current drug tools are adequate for control at this time
and may have impact in a limited number of elimination
situations. However a major research and development ef-
fort will be required to ensure that practical tools are
available when needed for major eradication push in much
of the malaria-endemic world (such as sub-Saharan Africa
and the Indian sub-continent). To be able to focus the re-
sources and expertise of the malaria community and its
supportive funders most effectively, well coordinated plans
and clear priorities are necessary. These need to be devel-
oped by the community working together so that clear
and non-fragmented messages can be delivered to funders
and policy-makers.
The CRIMALDDI Project, and its process of inter-
active workshops, has allowed the development of a set
of prioritized recommendations to inform the setting of
a future anti-malarial drug discovery agenda. These rec-
ommendations represent the consensus views of the par-
ticipants in the workshops, drawn both from the malaria
community and also drawing on expertise from outside
the community, bringing in new insights to key chal-
lenges. The prioritization process and the development
of a roadmap (including an estimate of cost and timing
for the priorities) allows funding agencies to have a more
integrated view of the strategic needs of anti-malarial
drug discovery at this crucial time. It describes a coor-
dinated action plan for European Union support for
malaria research: one which can also contribute to the
agenda-setting discussions among other global funding
agencies. It was not the role of the CRIMALDDI pro-
ject to allocate how this funding should be raised be-
tween possible funding agencies. However we hope that
it will stimulate discussion and co-ordination between
the agencies to maximize the use of scarce resources
and to avoid unnecessary duplication of effort. The
methodology of bringing together groups of experts in
a particular field for interactive and facilitated work-
shops has proven to be a valuable way of arriving at
consensus recommendations. This and the process of
then strictly prioritizing recommendations, according
to pre-agreed criteria, may be of value for similar initia-
tives in the future.timing needed to deliver the prioritized recommendations classified
Figure 3 Action plan to deliver “removing key roadblocks”. The estimates of costs and timing needed to deliver the prioritized
recommendations classified as “key roadblocks”.
Figure 4 Action plan to deliver “speeding up drug discovery”. The estimates of costs and timing needed to deliver the prioritized
recommendations classified as “speeding up drug discovery”.
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